Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Shuichi Amaki is active.

Publication


Featured researches published by Shuichi Amaki.


Journal of Autoimmunity | 2003

Profile and clinical significance of anti-nuclear envelope antibodies found in patients with primary biliary cirrhosis: a multicenter study

Kiyomitsu Miyachi; Raleigh W. Hankins; Hiroshi Matsushima; Futoshi Kikuchi; Tetushi Inomata; Tuneyoshi Horigome; Minoru Shibata; Yasushi Onozuka; Yukihisa Ueno; Etsuko Hashimoto; Naoaki Hayashi; Akitaka Shibuya; Shuichi Amaki; Hiroshi Miyakawa

Primary biliary cirrhosis (PBC) sera contain antibodies which recognize various nuclear envelope proteins of which antibody against gp210 has been proven to be diagnostic for disease. In contrast, the clinical significance of another nuclear envelope antibody, anti-p62 antibody has not been well investigated. In the present study, we have analyzed anti-nuclear envelope antibodies by indirect immunofluorescence and immunoblot using rat liver nuclear envelope proteins and wheat germ agglutinin-bound fraction. Test sera were obtained from 175 patients with PBC and from 120 controls. Anti-gp210, anti-lamina associated polypeptide 2, anti-lamin B receptor, and anti-p62 complex antibodies were detected with a frequency of 26% (46 of 175), 6% (11 of 175), 9% (16 of 175), and 13% (15 of 115), respectively. The confirmation of Scheuers stage IV was made with a frequency of 27% (4 of 15) in PBC patients with anti-p62 complex antibody, in contrast to only 2% (2 of 100) in PBC patients without anti-p62 complex antibody. This difference was found to be statistically significant. The presence of anti-p62 complex antibody may be related with the progressive or advanced state of PBC.


Journal of Gastroenterology | 2004

PBC-AIH overlap syndrome with concomitant ITP and Hashimoto's disease with positivity for anti-centromere antibody.

Yasuo Arakawa; Shuichi Amaki; Hiroshi Miyakawa; Toshimitsu Sakai; Iori Gotou; Naohide Tanaka; Mitsuhiko Moriyama; Ariyoshi Iwasaki; Masahiko Sugitani; Yasuyuki Arakawa

We report a case of primary biliary cirrhosis (PBC)-autoimmune hepatitis (AIH) overlap syndrome with concurrent idiopathic thrombocytopenic purpura (ITP) and Hashimoto’s disease with positivity for anticentromere antibody. The patient was a 64-year-old woman with symptoms of jaundice and general fatigue. About 30 years earlier, she had been diagnosed as having ITP and had undergone splenectomy. As part of her present history, she had exhibited liver dysfunction in 1995, during the follow-up of Hashimoto’s disease, and a liver biopsy led to the diagnosis of PBC. In March 2000, she was admitted to hospital because of general fatigue and jaundice. Blood tests revealed: total protein (TP), 6.6 g/dl; γ-globulin (glb), 35.9%; total bilirubin (T-bil), 9.41 mg/dl; direct bilirubin (D-bil), 7.52 mg/dl; aspartate aminotransferase (AST), 957 U/l; alanine aminotransferase (ALT), 651 U/l; alkaline phosphatase (ALP), 595 U/l; γ-guanosine triphosphate (GTP), 129 U/l; IgG, 2620 mg/dl; IgM, 223 mg/dl; hepatitis B surface antigen (HBsAg), negative; anti-hepatitis C virus (HCV), negative; antinuclear antibody, positive; antimitchondrial antibody (AMA), negative (by the immunofluorescence [IF] method); and anti-pyruvate dehydrogenase complex (PDC)-E2 antibody, positive (by Western blotting). Anticentromere antibody (ACA), which is an alternative diagnostic marker for PBC, was detected in this patient. Prednisolone was administered after admission and liver function test results improved markedly. The liver biopsy in 1995 had revealed infiltration of lymphocytes and plasma cells in the portal areas with fibrous expansion and periportal necrosis. Destructive cholangitis was observed, as well as scattered epitheloid cell granulomas in some portal areas. Liver biopsy after the steroid treatment revealed alleviated necrotic inflammatory responses of hepatocytes, while the destructive cholangitis persisted. This is a very rare case of PBC-AIH overlap syndrome accompanied by ITP and Hashimoto’s disease which provides a possible insight into the mechanisms and interplay of autoimmune diseases.


Immunogenetics | 2006

Genetic variants of the IgA Fc receptor (FcαR, CD89) promoter in chronic hepatitis C patients

Azuma Watanabe; Toshibumi Shimokawa; Mitsuhiko Moriyama; Fumihiko Komine; Shuichi Amaki; Yasuyuki Arakawa; Chisei Ra

Fc receptor for IgA (FcαR, CD89) is capable of triggering IgA-mediated immune responses to pathogens and has been proposed to function in circulating IgA clearance. Because inheritable variations modifying individual immune responses or immunoglobulin catabolism may affect the chronicity of viral infection, we investigated whether promoter polymorphisms of the FcαR gene (FCAR) affect chronic hepatitis C virus (HCV) infection and its disease progression. The two −311T/C and −142T/C single-nucleotide polymorphisms (SNPs) were studied by direct DNA sequencing in 177 Japanese patients with chronic hepatitis C (CHC). Both −311CC and −142CC genotypes were more frequent in CHC patients (15.9 and 18.6%) compared with 210 healthy controls (5.7 and 10.0%) [p = 0.001, odds ratio (OR) = 3.10, 95% confidence interval CI) = 1.53–6.30 and p = 0.014, OR = 2.06, 95% CI = 1.14–3.72, respectively], and were associated with infection with HCV genotype 2a/2b (p = 0.019 and p = 0.005, respectively). Conversely, −311CC and −142CC were decreased in 59 patients at advanced stages of disease as assessed on the basis of hepatic fibrosis markers such as decreased platelet count (PLT) ( < 150,000/μl) (5.1 and 8.5%) compared with 91 patients with normal PLT ( ≥ 150,000/μl) (24.2 and 26.4%) (p = 0.006 and p = 0.005, respectively). Moreover, among the patients with normal PLT (but not with decreased PLT), −311CC or −142CC was significantly associated with decreased serum IgA levels (p = 0.023 or p = 0.007, respectively). These results suggest that the FCAR promoter SNPs may be related to chronic HCV infection and disease progression in Japanese CHC, which might be explained by altered FcαR expression affecting IgA-mediated immune responses and/or IgA catabolism.


International Hepatology Communications | 1993

Ultrastructural study of HBx antigen in liver from chronic hepatitis B patients

Mitsuhiko Moriyama; Kazutomo Suzuki; Shuichi Amaki; Naohide Tanaka; Hitoshi Ohkubo; Ishizuka Hideo; Yasuyuki Arakawa; Yutaka Matsuo; Kohyu Suzuki; Toshikazu Uchida; Toshio Shikata; Noboru Yanaihara

Abstract We examined the localization of intrahepatic HBx and HBc antigen in patients with chronic hepatitis B using immuno-electron microscopy. HBx antigen is detected on endoplasmic reticulum in the cytoplasm of hepatocytes, and is localized at almost the same site as the HBc antigen. These studies suggested that HBx antigen appears to be associated with HBV replication in one way or another.


Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine | 1989

[A case of the right atrium-originating hemangiosarcoma manifested by cardiac tamponade].

Shuichi Amaki; Akihumi Ogiwara; Motoo Endo; Hisayuki Ariga; Yasuyuki Arakawa; Yutaka Matsuo; Naosi Tanigawa; Kouyuu Suzuki

症例は64才の男性.胸背部痛を主訴に緊急入院となる.心タンポナーデと診断し,心膜穿刺を行い血性の心膜液が得られた.心エコーで右房より三尖弁に至る紐状エコーを認め,これは収縮期および拡張期共に三尖弁の動きに同調していた.血痰が持続し,肺野に結節状陰影およびその周囲に浸潤影を認めた.肋骨への転移を認め,心膜液貯留が持続するため肋骨,肺の生検および心膜開窓術を行い,心原発の血管肉腫であることが診断確定した.


Journal of Clinical Biochemistry and Nutrition | 2009

Zinc supplementation improves the outcome of chronic hepatitis C and liver cirrhosis.

Shunichi Matsuoka; Hiroshi Matsumura; Hitomi Nakamura; Shu Oshiro; Yasuo Arakawa; Junpei Hayashi; Naoki Sekine; Kazushige Nirei; Hiroaki Yamagami; Masahiro Ogawa; Noriko Nakajima; Shuichi Amaki; Naohide Tanaka; Mitsuhiko Moriyama


Digestive Diseases and Sciences | 2007

Factors Influencing Treatment Efficacy of 24-Week Combination Therapy with Interferon α-2b Plus Ribavirin for Chronic Hepatitis C

Mitsuhiko Moriyama; Hiroshi Matsumura; Kazushige Nirei; Yasuo Arakawa; Hiroaki Yamagami; Masahiro Ogawa; Miki Kaneko; Shuichi Matsuoka; Shuichi Amaki; Naohide Tanaka; Yasuyuki Arakawa


Japanese Journal of Medicine | 1986

Safety and Efficacy of Hepatitis B Vaccine in Hospital Personnel

Yasuyuki Arakawa; Shuichi Amaki; Masatoshi Miyamoto; Yutaka Matsuo; Toshio Honda; Toshio Shikata


Kanzo | 1993

Response of liver histology to interferon therapy with chronic hepatitis B and C.

Mitsuhiko Moriyama; Fumihiko Komine; Atsuo Shiota; Junko Moriyama; Hiroshi Saitoh; Keizo Fujibayashi; Takashi Motohashi; Kazutomo Suzuki; Shuichi Amaki; Naohide Tanaka; Hitoshi Ohkubo; Hideo Ishizuka; Yoshiki Ono; Yasuyuki Arakawa; Yutaka Matsuo; Nakanobu Hayashi; Masahiko Sugitani; Kohyu Suzuki; Toshikazu Uchida; Toshio Shikata


Kanzo | 1991

Detection of serum HCV antibody ELISA assay using to the C-100 synthetic peptide.

Mitsuhiko Moriyama; Tomohide Takahashi; Nakanobu Hayashi; Toshio Shikata; Junko Moriyama; Shuichi Amaki; Naohide Tanaka; Masahiko Tokoro; Hitoshi Ohkubo; Yasuyuki Arakawa; Yutaka Matsuo; Masakatsu Hashimoto; Kunihiro Nitta; Kiichiro Nakajima

Collaboration


Dive into the Shuichi Amaki's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge